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Abstract
Mild-cognitive impairment (MCI) occurs in up to one-ﬁfth of individuals over the age of 65, with approximately a third
of MCI individuals converting to dementia in later life. There is a growing necessity for early identiﬁcation for those at
risk of dementia as pathological processes begin decades before onset of symptoms. A cohort of 122 individuals
diagnosed with MCI and followed up for a 36-month period for conversion to late-onset Alzheimer’s disease (LOAD)
were genotyped on the NeuroChip array along with pathologically conﬁrmed cases of LOAD and cognitively normal
controls. Polygenic risk scores (PRS) for each individual were generated using PRSice-2, derived from summary statistics
produced from the International Genomics of Alzheimer’s Disease Project (IGAP) genome-wide association study.
Predictability models for LOAD were developed incorporating the PRS with APOE SNPs (rs7412 and rs429358), age and
gender. This model was subsequently applied to the MCI cohort to determine whether it could be used to predict
conversion from MCI to LOAD. The PRS model for LOAD using area under the precision-recall curve (AUPRC)
calculated a predictability for LOAD of 82.5%. When applied to the MCI cohort predictability for conversion from MCI
to LOAD was 61.0%. Increases in average PRS scores across diagnosis group were observed with one-way ANOVA
suggesting signiﬁcant differences in PRS between the groups (p < 0.0001). This analysis suggests that the PRS model
for LOAD can be used to identify individuals with MCI at risk of conversion to LOAD.
Introduction
The genetic contribution to late-onset Alzheimer’s
disease (LOAD) is now well established, with heritability
estimates ranging from 58 to 79%1. The APOE gene
located on Chromosome 19 encodes the Apolipoprotein E
protein. This gene represents the largest genetic risk
factor for LOAD to date, with genetic variation producing
three isoforms: ε2 (protective), ε3 (neutral and most
common form) and ε4, which is associated with increased
risk for LOAD. Further to this a number of both common
and rare genetic risk factors have been identiﬁed in recent
years from genome-wide association studies (GWAS) and
next-generation sequencing efforts2–5. Despite this
increase in our knowledge of genetic associations these do
not account for the entire heritability of the LOAD phe-
notype. Although other factors such as epistasis and epi-
genetics might contribute, it is becoming accepted that far
more genes/polymorphisms with much smaller effect
sizes are involved in complex diseases than previously
envisaged.
Genetic risk calculation studies have typically used only
variants identiﬁed by GWAS to try and predict LOAD
phenotype6–12, mild- cognitive impairment (MCI) con-
version to LOAD13,14, hippocampal cortical thickness15,16,
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hippocampal volume17, cerebrospinal ﬂuid biomarkers18
and plasma inﬂammatory biomarkers19.
The development of polygenic risk score (PRS) analysis
now allows for the sum of genetic risk from the entire
genome to be accounted for, weighted by the effect size
estimates attained from established GWAS data, rather
than selecting a few speciﬁc associated single-nucleotide
polymorphism (SNP) markers20. The study by Escott-
Price et al.21 demonstrated that the predictability of
LOAD from APOE isoform and contribution of the
LOAD GWAS SNPs was improved by incorporating
further variants from across the genome into their PRS
model. The addition of other predictors such as gender
and age into the model resulted in a ﬁnal predictive ability
of 78.2%. Several other studies have also demonstrated
that this form of analysis can differentiate between con-
trols and LOAD cases with similarly high accuracy22,23.
The pathological features of LOAD have been found to
begin decades before the onset of symptoms24–26.
Therefore, the early detection of those likely to be at risk
for LOAD could increase effectiveness of treatments
preventing further damage from occurring25,26. MCI is
diagnosed in up to one-ﬁfth of individuals over the age of
65 and is considered a prodrome of dementia25. An esti-
mated one-third of those diagnosed with MCI will go on
to develop LOAD over time27. Consequently, under-
standing genetic risk factors within LOAD pathogenic
mechanisms can improve detection and promote treat-
ment before the pathogenic state arises24,26,28. A ther-
apeutic intervention at the MCI stage may provide an
opportunity to prevent or delay conversion to LOAD13,29.
Therefore, there is a need to investigate if MCI to LOAD
conversion can be predicted using PRS analysis.
In this study, we developed a PRS model to predict
LOAD diagnosis in the brains for dementia research
(BDR) cohort30. This model was then applied to a long-
itudinal sample of individuals with MCI from the South-
ampton inﬂammation, cognition and stress (ICOS) study,
to see if the model could predict those individuals who
converted from MCI to LOAD.
Materials and methods
Samples
The BDR resource has recruited patients with dementia
as well as cognitively healthy controls; post-mortem
pathology was used to conﬁrm and classify disease sta-
tus31. This cohort consists of 302 LOAD cases and 137
controls, with no signiﬁcant differences in the age at death
and percentage of females between the cases and controls.
The number of ε4 carriers was signiﬁcantly higher
amongst cases (p < 0.001; Table 1) as expected.
Individuals with MCI were recruited from the ICOS study
in Southampton, UK. Diagnoses were made using the
Petersen criteria for amnestic MCI32. The study followed-
up individuals over a 36-month period (until October 2017)
to identify those who converted to a LOAD (‘converters’ n
= 49), and those who remained MCI (‘non-converters’ n=
73). Age at recruitment and presence of at least one APOE
ε4 allele was not found to be signiﬁcantly different between
the converters and non-converters; although the converter
group was found to have a signiﬁcantly higher proportion of
females (p= 0.008; Table 1).
Genotyping
DNA extraction was performed using a standard phenol
chloroform method on either 2ml of blood (MCI) or
100mg of brain tissue (BDR). DNA quality was assessed
using the Agilent 2200 TapeStation DNA integrity number
(DIN; average DIN= 8.95) and quantiﬁed using Nanodrop
3300 spectrometry. All samples were collected with
informed consent as governed by local guidelines at the
point of collection; experimental procedures were approved
by local ethics committees - Nottingham Research Ethics
Committee 2 (REC reference 04/Q2404/130); London City
and East NRES (REC reference 08/H0704/128+ 5), and
completed in accordance with approved guidelines.
Genotyping was performed on the customised Neu-
roChip array33. Clustering was completed with the assis-
tance of a cluster ﬁle provided by Blauwendraat and
colleagues (2017) and the dataset was aligned to the
GRCh37/hg19 assembly using ﬁles provided by Rayner, W
(Personal correspondence, Nov 2017). Quality control of
the raw data was completed using GenomeStudio v2 and
PLINK v1.934, with samples removed based on a call rate
less than 90%, gender mismatch and deviation from
European population parameters. SNPs were removed
based on a call rate less than 95%, genotype frequencies
signiﬁcantly out of Hardy–Weinberg equilibrium with a
Bonferroni corrected p value threshold (p= 1.03 × 10−7)
Table 1 Demographics of each group genotyped




BDR LOAD cases 302 83.0 146 (48.3) 196 (64.9) 39 (12.9)
Controls 137 84.0 68 (49.6) 49 (40.1) 2 (1.5)
ICOS MCI Non-
converters
73 76.0 21 (28.8) 31 (42.5) 4 (5.5)
MCI
converters
49 79.0 26 (53.1) 23 (46.9) 4 (8.2)
The late-onset Alzheimer’s disease (LOAD) cases and controls were recruited
from the brains for dementia research (BDR) resource. The individuals with mild-
cognitive impairment (MCI) were recruited from a single study in Southampton,
UK; conversion to LOAD was identiﬁed after 36-month follow-up. LOAD cases
were shown to harbour more APOE ε4+ individual than controls (p < 0.001), but
no signiﬁcant differences were observed between the proportion of females or
age at death. MCI converters were shown to have a signiﬁcantly higher
proportion of females in comparison to the non-converters (p= 0.008), with no
signiﬁcant differences observed for age or APOE ε4+ carriers.
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and excess heterozygosity (±3 standard deviations from
mean). SNPs where the minor allele was observed in less
than 3 individuals were also removed.
The APOE SNPs rs7412 and rs429358 (which determine
the isoform) were genotyped with TaqMan assays using
standard protocols. At least one APOE ε4 allele was har-
boured by 70.9% of LOAD cases, 46.9% of MCI con-
verters, 42.9% of MCI non-converters and 40.1% of
controls (Table 1).
Polygenic-risk score generation and predictability
modelling
The APOE gene is the largest known risk factor for
LOAD, with the region surrounding the locus displaying
levels of strong linkage disequilibrium (LD). Therefore,
SNPs which fell within the 500 kb region
(chr19:45,160,844-45,660,844; GRCh37/hg19 assembly)
surrounding the APOE gene were excluded from the
dataset. The genotypes for the APOE ε status SNPs
(rs7412 and rs429358) were then reintroduced to the
dataset to ensure genetic risk from APOE was captured.
Samples from the 1000 Genomes Project Consortium
(1000G; n= 2504) were compared ancestrally to the BDR
and MCI samples using common ancestry informative
markers. Principal component analysis was carried out in
PLINK to verify all NeuroChip-genotyped samples (n=
561) fell within the cluster of European descent (n= 503)
to guard against population stratiﬁcation.
Data from the 1000G samples were also used to calcu-
late LD structure. The clumping algorithm in PRSice-220
was set to identify any SNPs within 250 kb in LD with an
r2 threshold greater than 0.1 and ‘clump’ them together to
be represented by most signiﬁcantly associated SNP
within each LD block, denoted the index SNP.
PRSice-2 was utilised to generate PRS for LOAD cases
and cognitively healthy controls, using summary statistic
data from the International Genomics of Alzheimer’s
Disease Project (IGAP) genome-wide association study35.
Signiﬁcance values and effect sizes from the IGAP cohort
were used as the base dataset to generate the best PRS
model which was then applied to the BDR and MCI target
datasets. Brieﬂy, the PRS for each individual in the target
dataset is generated from a summation of effect sizes from
all the SNPs included in the best model. The best model
was derived from testing the inclusion of SNPs
(19–73,058 SNPs) from a range of p value thresholds in
the base dataset (10−6 to 1), to see which threshold gave
the largest Nagelkerke’s R2 value. These SNPs were then
used to generate PRS for each individual in both the BDR
and MCI cohorts.
The signiﬁcance of differences in mean PRS between
the four groups (controls, MCI non-converters, MCI
converters and LOAD) was tested using one-way ANOVA
with post hoc Tukey in SPSS v24. Spearman’s correlation
analysis was also conducted by ranking the diagnosis
groups from 0 (control), 1 (non-converters), 2 (con-
verters) to 3 (LOAD).
Predictive ability of APOE alone and APOE with the
PRS for identifying LOAD cases and converters in each
cohort was calculated using Area Under the precision-
recall Curve (AUPRC) in R using the ‘PRROC’ package36
(R Core Team, 2013). AUPRC was calculated to identify
predictive ability, values range from 0 to 100%, where 0%
is random classiﬁcation and 100% is perfect
classiﬁcation37.
The effect of non-genetic predictors (age and gender)
were estimated in SPSS, and were included with PRS in
logistic regression analysis to enable incorporation into
the predictive model.
LOAD cases and controls were distributed into deciles
based on the range of probability values which accounted
for PRS with APOE, gender and age at death. The pro-
portions of LOAD cases which fell into each decile were
calculated and are depicted alongside the proportion of
controls within the same decile. This was also conducted
for the proportions of MCI converters and non-
converters within each decile distributed by PRS includ-
ing APOE, gender and age at recruitment.
Results and discussion
European ancestry of the BDR and MCI samples was
conﬁrmed with principal component analysis, as all
samples clustered accordingly with European samples
from the 1000G dataset. A plot of the ﬁrst two principal
components is presented in Supplementary Fig. 1. With
conﬁrmation that the BDR and MCI target datasets were
or the same ethnic decent as the IGAP base dataset,
analysis could proceed.
PRSice-2 derived Nagelkerke’s R2 values for a range of
SNP p value thresholds from 1 × 10−6 to 1 in the IGAP
base dataset were used to determine the best signiﬁcance
threshold for inclusion of SNPs required to distinguish
between LOAD cases and controls. There was a total of
73,056 SNPs were found in both the IGAP base dataset
and NeuroChip target datasets after LD based clumping
(r2 > 0.1; kb= 250). The largest Nagelkerke’s R2 value
generated was 0.138, suggesting the inclusion of all SNPs
at the p value threshold of 1.07 × 10−4 into the PRS model
plus the two APOE SNPs (total 167 SNPs; Supplementary
Table 1). This model was then applied to both the BDR
and MCI cohorts.
One-way ANOVA analysis of mean PRS scores between
diagnosis groups, suggested an overall signiﬁcance in PRS
score (p < 0.0001). Pairwise post hoc Tukey analysis of the
groups showed that the mean PRS of the BDR LOAD
samples were found to be signiﬁcantly higher than that of
the controls (p < 0.0001 post hoc Tukey), likewise the
mean PRS for the MCI converters was found to be higher
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than that of MCI non-converters, however this was not
signiﬁcant (Fig. 1). Post hoc Tukey also identiﬁed sig-
niﬁcant differences in mean PRS between non-converters
and LOAD samples (p < 0.0001).
Predictability of the LOAD phenotype with PRS,
including APOE with gender and age at death incorpo-
rated into the model, produced a ﬁnal AUPRC for pre-
dictability for LOAD of 82.5%. The APOE genotypes alone
were found to have a predictability of 81.8%. When
applied to the MCI cohort for predictability of conversion
with age at recruitment in the study instead of age at
death, the full model produced a predictability of 61.0%
for conversion, with APOE alone showing 43.8% pre-
dictability. This demonstrates the utility of the PRS to
discern conversion from MCI to LOAD.
Samples for the BDR and MCI cohorts were separately
partitioned into deciles of increasing disease risk based on
PRS, including APOE genotypes, gender and age; the
proportion of LOAD cases and controls which fell into
each decile are depicted in Fig. 2. As of December 2017,
49 individuals diagnosed with MCI had converted to
LOAD (39.3%); the proportion of converters and non-
converters which fell into each decile are also given in Fig.
3. Both ﬁgures show the proportion of LOAD/MCI con-
verters increases with increasing PRS.
PRS is increasingly being used in genetic analyses to
determine predictability of complex disease. In this study,
cognitively healthy controls and individuals with LOAD
or MCI were genotyped on the NeuroChip array33. PRS
were generated from IGAP summary statistics and use to
calculate risk scores for LOAD cases and controls from
the BDR and MCI samples from the Southampton ICOS
cohort. The best predictive model (82.5%) to distinguish
LOAD cases from controls generated in the BDR cohort
was found to be able to predict LOAD converters in the
MCI cohort with an accuracy of 61.0%.
The difference between mean PRS of controls, non-
converters, converters and LOAD cases was signiﬁcant
with one-way ANOVA, however, pairwise signiﬁcance
(post hoc Tukey) was only observed between LOAD cases
and controls and LOAD cases and MCI non-converters.
The distribution proﬁle in Fig. 1 and Spearman’s rank
order correlation (r= 0.408; p= 0.01) conﬁrms an
increased PRS with disease status from control through
non-converters, converters to LOAD. The lack of a sig-
niﬁcant difference in average PRS between the MCI non-
converters and converters is mostly like due to the small
sample sizes, and it is expected that with increased
numbers in each MCI group the mean PRS will move
towards controls and LOAD cases, respectively. This
hypothesis is supported by several studies suggesting that
possession of LOAD-risk alleles are associated with faster
cognitive decline, MCI and conversion from MCI to
LOAD13,38–40, with one study concluding that carrying 6
or more of the non-APOE LOAD risk alleles rapidly
increases conversion from MCI to LOAD14.
The resulting risk model, incorporating the APOE
SNPs, 165 non-APOE SNPs, gender and age successfully
predicted LOAD cases from controls with 82.5% accuracy
which is a similar value to previous studies21–23,25.
As observed in previous PRS analyses41 there are a
number of controls with high risk scores and cases of
LOAD individuals with a low-risk scores (Fig. 2). It is
possible that in these individuals, lifestyle and environ-
mental factors could be determining the disease presence
independent of, or interacting with genetic factors. Con-
trols with higher PRS might represent individuals who
would have developed disease had they lived longer as the
average age at death of controls in the highest decile was
signiﬁcantly lower (73.5 ± 7.8 years) compared with the
lowest decile (86.3 ± 5.0 years; p= 0.032). It is also pos-
sible that these individuals harbour unknown protective
factors which may reduce disease risk.
Further study highlighted signiﬁcantly later age at death
in LOAD cases with the lowest risk compared to LOAD
cases with the greatest risk (average age at death of LOAD
in decile 1= 95.0 ± 11.3; average age at death of LOAD in
decile 10= 81.1 ± 6.4; p= 0.007); this aligns with previous
studies identifying later age at onset in cases with low PRS
Fig. 1 Distribution of polygenic risk score (PRS), including APOE
SNPs (N= 167) amongst late-onset Alzheimer’s disease (LOAD)
cases, converters and non-converters from mild-cognitive
impairment (MCI), and controls. The range of scores for individuals
within each group are described in the ﬁgure (grey circles) with the
average PRS for each group indicated by the black circle. Signiﬁcant
differences were observed with one-way ANOVA across all four
groups (p < 0.0001), with post hoc Tukey indicating signiﬁcance
between pairwise comparisons indicated with ****(p < 0.0001)
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and increased prevalence with age;42,43. This could indi-
cate that genetic load is associated with onset and/or
severity of disease.
Predictive ability for LOAD conversion from MCI
(61.0%) was less than between controls and LOAD
(82.5%). This lower predictive ability is likely due to the
smaller sample size of the MCI cohort, furthermore the
ICOS cohort is a longitudinal study, and therefore unlike
the BDR cohort which have the diagnoses post-mortem
veriﬁed, the participants are still being clinically and
cognitively assessed. It is possible that as the study pro-
gresses further individuals in this study will convert and
inﬂuence the accuracy of the model.
The ability of the LOAD PRS model to predict to some
degree the conversion of MCI to LOAD, highlights a
possible genetic basis for conversion. Whereas non-
Fig. 2 Proportion of late-onset Alzheimer’s disease (LOAD) cases and cognitively healthy controls in each decile using the best predictive
model. Individual probabilities were generated using PRSice-2. The polygenic risk scores (PRS) including APOE and covariates for gender and age at
death were used to distribute individuals into deciles. The dark bars represent the proportion of LOAD cases which fall into each decile and the light
bars represent the proportion of controls. The number of LOAD cases and controls who fall within each decile are indicted in each block
Fig. 3 Proportion of mild cognitive impairment (MCI) non-converters and those who converted to late-onset Alzheimer’s disease.
Individual probabilities for the best predictive model were generated from polygenic risk scores (PRS) including APOE and covariates for gender and
age at recruitment to distribute individuals into deciles. The dark bars represent the proportion of converting MCIs in each decile and the light bars
represent the proportion of non-converting MCIs. The number of converters and non-converters who fall within each decile are listed
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converters have a genetic risk similar to that of controls,
they may still harbour some genetic variations associated
with LOAD which leads to the MCI phenotype though
those with the lowest scores may never convert to LOAD.
Conversely, the MCI subjects that did convert to LOAD
have a PRS that is not signiﬁcantly different to LOAD
cases, which reinforces the idea that MCI can be seen as a
prodromal state of LOAD and that by using approaches
such as we describe, those at risk of developing LOAD can
potentially be identiﬁed before the onset of LOAD
symptoms and would be the best candidates to evaluate
emerging therapeutic approaches.
Acknowledgements
We thank the International Genomics of Alzheimer’s Project (IGAP) for
providing summary results data for these analyses. The investigators within
IGAP contributed to the design and implementation of IGAP and/or provided
data but did not participate in analysis or writing of this report. IGAP was made
possible by the generous participation of the control subjects, the patients,
and their families. The i-Select chips were funded by the French National
Foundation on Alzheimer’s disease and related disorders. EADI was supported
by the LABEX (laboratory of excellence programme investment for the future)
DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2, and the
Lille University Hospital. GERAD was supported by the Medical Research
Council (Grant no. 503480), Alzheimer’s Research UK (Grant no. 503176), the
Wellcome Trust (Grant no. 082604/2/07/Z), and German Federal Ministry of
Education and Research (BMBF): Competence Network Dementia (CND) grant
nos. 01GI0102, 01GI0711, and 01GI0420. CHARGE was partly supported by the
NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01-
AG-12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and
the Erasmus Medical Center and Erasmus University. ADGC was supported by
the NIH/NIA grants: U01 AG032984, U24 AG021886, and U01 AG016976, and
the Alzheimer’s Association grant ADGC-10-196728. We gratefully
acknowledge all donors and their families for the tissue provided for this study.
Human post-mortem tissue was obtained from the South West Dementia
Brain Bank, London Neurodegenerative Diseases Brain Bank, Manchester Brain
Bank, Newcastle Brain Tissue Resource and Oxford Brain Bank, members of the
Brains for Dementia Research (BDR) Network. The BDR is jointly funded by
Alzheimer’s Research UK and the Alzheimer’s Society in association with the
Medical Research Council. We also acknowledge the neuropathologists at each
centre and BDR Brain Bank staff for the collection and classiﬁcation of the
samples. The South West Dementia Brain Bank is part of the Brains for
Dementia Research programme, jointly funded by Alzheimer’s Research UK
and Alzheimer’s Society, and is supported by BRACE (Bristol Research into
Alzheimer’s and Care of the Elderly) and the Medical Research Council. We
thank the donor whose donation of brain tissue to the London
Neurodegenerative Diseases Brain Bank allowed this work to take place. The
Brain Bank is supported by the Medical Research Council and Brains for
Dementia Research (jointly funded by the Alzheimer’s Society and Alzheimer’s
Research UK). We acknowledge the support of the Manchester Brain Bank by
Alzheimer’s Research UK and Alzheimer’s Society through their funding of the
Brains for Dementia Research (BDR) Programme. Manchester Brain Bank also
receives Service Support costs from Medical Research Council. Tissue provided
by the Newcastle Brain Tissue Resource is funded, in part, by a grant from the
UK Medical Research Council (G0400074), by NIHR Newcastle Biomedical
Research Centre and Unit awarded to the Newcastle upon Tyne NHS
Foundation Trust and Newcastle University, and by a grant from the
Alzheimer’s Society and Alzheimer’s Research UK as part of the Brains for
Dementia Research Project. Tissue for this study was provided by the
Newcastle Brain Tissue Resource, which is funded, in part, by a grant from the
UK Medical Research Council (G0400074) and by Brains for Dementia research,
a joint venture between Alzheimer’s Society and Alzheimer’s Research UK. We
acknowledge the Oxford Brain Bank, supported by the UK MRC, the NIHR
Oxford Biomedical Research Centre and the Brains for Dementia Research
programme for providing post-mortem specimens. Jose Bras and Rita
Guerreiro’s work is funded by Fellowships from the Alzheimer’s Society. The
ICOS study was funded by the Alzheimer’s Society (PG 143/150). The Human
Genetics Group at the University of Nottingham was supported by Alzheimer’s
Research UK (Program Grant 2809) to conduct genotyping and analyses of the
BDR cohort and SC was supported by a PhD studentship from the
Neurosciences Group at Queen’s Medical Centre (Nottingham) and the School
of Life Sciences, University of Nottingham. We thank Dr William Rayner of The
Wellcome Trust of Human Genetics for providing the strand ﬁles for alignment
of the NeuroChip to the GRCh37 assembly.
Author details
1Human Genetics Group, University of Nottingham, Nottingham, UK. 2UK
Dementia Research Institute at University College London and ION
Department of Neurodegenerative Disease, London, UK. 3Brains for Dementia
Research Resource, Wolfson CARD, King’s College London, London, UK.
4Faculty of Medicine, University of Southampton, Southampton, UK. 5Institute
of Neuroscience Biomedical Research Building Campus for Ageing and Vitality
Newcastle University, Newcastle upon Tyne NE4 5PL, UK
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Supplementary information accompanies this paper at (https://doi.org/
10.1038/s41398-019-0485-7).
Received: 10 January 2019 Revised: 5 April 2019 Accepted: 10 April 2019
References
1. Gatz, M. et al. Role of genes and environments for explaining Alzheimer
disease. Arch. Gen. Psychiatry 63, 168–174 (2006).
2. Guerreiro, R. et al. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med. 368,
117–127 (2013).
3. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer’s
disease. N. Engl. J. Med. 368, 107–116 (2013).
4. Lambert, J. C. et al. Genome-wide association study identiﬁes variants at CLU
and CR1 associated with Alzheimer’s disease. Nat. Genet. 41, 1094–1099
(2009).
5. Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate
microglial-mediated innate immunity in Alzheimer’s disease. Nat. Genet. 49,
1373–1384 (2017).
6. Chouraki, V. et al. Evaluation of a Genetic Risk Score to Improve Risk Prediction
for Alzheimer’s Disease. J. Alzheimers Dis. 53, 921–932 (2016).
7. Marden, J. R. et al. Using an Alzheimer Disease Polygenic Risk Score to Predict
Memory Decline in Black and White Americans Over 14 Years of Follow-up.
Alzheimer Dis. Assoc. Disord. 30, 195–202 (2016).
8. Desikan, R. S. et al. Genetic assessment of age-associated Alzheimer disease
risk: Development and validation of a polygenic hazard score. PLoS Med. 14,
e1002258 (2017).
9. Sleegers, K. et al. A 22-single nucleotide polymorphism Alzheimer’s disease risk
score correlates with family history, onset age, and cerebrospinal ﬂuid
Abeta42. Alzheimers Dement. 11, 1452–1460 (2015).
10. Verhaaren, B. F. et al. Alzheimer’s disease genes and cognition in the non-
demented general population. Biol. Psychiatry 73, 429–434 (2013).
11. Xiao, Q. et al. Risk prediction for sporadic Alzheimer’s disease using genetic
risk score in the Han Chinese population. Oncotarget 6, 36955–36964
(2015).
12. Yokoyama, J. S. et al. Decision tree analysis of genetic risk for clinically het-
erogeneous Alzheimer’s disease. BMC Neurol. 15, 47 (2015).
13. Adams, H. H. et al. Genetic risk of neurodegenerative diseases is associated
with mild cognitive impairment and conversion to dementia. Alzheimers
Dement. 11, 1277–1285 (2015).
14. Rodriguez-Rodriguez, E. et al. Genetic risk score predicting accelerated pro-
gression from mild cognitive impairment to Alzheimer’s disease. J. Neural
Transm. 120, 807–812 (2013).
Chaudhury et al. Translational Psychiatry           (2019) 9:154 Page 6 of 7
15. Harrison, T. M. et al. An Alzheimer’s disease genetic risk score predicts long-
itudinal thinning of hippocampal complex subregions in healthy older adults.
eNeuro 3, 0098–16 (2016).
16. Sabuncu, M. R. et al. The association between a polygenic Alzheimer score
and cortical thickness in clinically normal subjects. Cereb. Cortex. 22, 2653–2661
(2012).
17. Lupton, M. K. et al. The effect of increased genetic risk for Alzheimer’s
disease on hippocampal and amygdala volume. Neurobiol. Aging 40,
68–77 (2016).
18. Martiskainen, H. et al. Effects of Alzheimer’s disease-associated risk loci on
cerebrospinal ﬂuid biomarkers and disease progression: a polygenic risk score
approach. J. Alzheimers Dis. 43, 565–573 (2015).
19. Morgan, A. R. et al. The correlation between inﬂammatory biomarkers and
polygenic risk score in Alzheimer’s disease. J. Alzheimers Dis. 56, 25–36
(2017).
20. Euesden, J., Lewis, C. M. & O’Reilly, P. F. PRSice: polygenic risk score software.
Bioinformatics 31, 1466–1468 (2015).
21. Escott-Price, V. et al. Common polygenic variation enhances risk prediction for
Alzheimer’s disease. Brain 138(Pt 12), 3673–3684 (2015).
22. Escott-Price, V., Myers, A. J., Huentelman, M. & Hardy, J. Polygenic risk score
analysis of pathologically conﬁrmed alzheimer’s disease. Ann. Neurol. 82,
311–314 (2017).
23. Escott-Price, V., Shoai, M., Pither, R., Williams, J. & Hardy, J. Polygenic score
prediction captures nearly all common genetic risk for Alzheimer’s disease.
Neurobiol. Aging 49, 214 e7–e11 (2017).
24. Axelrud, L. K. et al. Polygenic risk score for Alzheimer’s disease: implications for
memory performance and hippocampal volumes in early life. Am. J. Psychiatry
175, 555–563 (2018).
25. Logue, M. W. et al. Use of an Alzheimer’s disease polygenic risk score to
identify mild cognitive impairment in adults in their 50s. Mol. Psychiatry 24,
421–430 (2018).
26. Mormino, E. C. et al. Polygenic risk of Alzheimer disease is associated with
early- and late-life processes. Neurology 87, 481–488 (2016).
27. Mitchell, A. J. & Shiri-Feshki, M. Rate of progression of mild cognitive impair-
ment to dementia—meta-analysis of 41 robust inception cohort studies. Acta
Psychiatr. Scand. 119, 252–265 (2009).
28. Tosto, G. & Reitz, C. Genome-wide association studies in Alzheimer’s disease: a
review. Curr. Neurol. Neurosci. Rep. 13, 381 (2013).
29. Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of
polygenic risk scores. Nat. Rev. Genet. 19, 581–590 (2018).
30. Francis, P. T., Costello, H. & Hayes, G. M. Brains for dementia research: evolution
in a longitudinal brain donation cohort to maximize current and future value.
J. Alzheimers Dis. 66(4), 1635–1644, https://doi.org/10.3233/JAD-180699 (2018).
31. Brookes, K. J. et al. Genotyping of the Alzheimer’s disease genome-wide
association study index single nucleotide polymorphisms in the brains for
dementia research cohort. J. Alzheimers Dis. 64, 355–362 (2018).
32. Sussams, R. et al. Systemic inﬂammatory responses to stress and its impact on
cognition in people with mild cognitive impairment. Alzheimer’s Dement. 9,
P775 (2013).
33. Blauwendraat, C. et al. NeuroChip, an updated version of the NeuroX geno-
typing platform to rapidly screen for variants associated with neurological
diseases. Neurobiol. Aging 57, 247.e9–247.e13 (2017).
34. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger
and richer datasets. Gigascience 4, 7 (2015).
35. Lambert, J.-C. et al. Meta-analysis of 74,046 individuals identiﬁes 11 new sus-
ceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013).
36. Grau, J., Grosse, I. & Keilwagen, J. PRROC: computing and visualizing precision-
recall and receiver operating characteristic curves in R. Bioinformatics 31,
2595–2597 (2015).
37. Saito, T. & Rehmsmeier, M. The precision-recall plot is more informative than
the ROC plot when evaluating binary classiﬁers on imbalanced datasets. PLoS
ONE 10, e0118432 (2015).
38. Carrasquillo, M. M. et al. Late-onset Alzheimer’s risk variants in memory decline,
incident mild cognitive impairment, and Alzheimer’s disease. Neurobiol. Aging
36, 60–67 (2015).
39. Jiang, Y., He, T., Deng, W. & Sun, P. Association between apolipoprotein E gene
polymorphism and mild cognitive impairment: a meta-analysis. Clin. Inter.
Aging 12, 1941–1949 (2017).
40. Moreno-Grau, S. & Ruiz, A. Genome research in pre-dementia stages of Alz-
heimer’s disease. Expert Rev. Mol. Med. 18, e11 (2016).
41. Chaudhury, S. et al. Polygenic risk score in postmortem diagnosed sporadic
early-onset Alzheimer’s disease. Neurobiol. Aging 62, 244 e1–e8 (2018).
42. Tan, C. H. et al. Polygenic hazard scores in preclinical Alzheimer disease. Ann.
Neurol. 82, 484–488 (2017).
43. Tosto, G. et al. Polygenic risk scores in familial Alzheimer disease. Neurology 88,
1180–1186 (2017).
Chaudhury et al. Translational Psychiatry           (2019) 9:154 Page 7 of 7
